In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism

References

• Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE. (2001). Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 69:96–103.
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Anzenbacherová E. (2001). Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737–747.
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, O’Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29–37.
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occuring variants. Drug Metab Dispos 32:775–778.
   PubMed Web of Science ®Google Scholar
• Boase S, Miners JO. (2002). In vitro-in vivo correlations for drugs cleared by glucuronidation: investigations with the model substrate, zidovudine. Br J Clin Pharmacol 54:493–503.
   PubMed Web of Science ®Google Scholar
• Burchell B, Lockley DJ, Staines A, Uesawa Y, Coughtrie MW. (2005). Substrate specificity of human hepatic UDP-glucuronosyltransferases. Methods Enzymol 400:46–57.
   PubMed Web of Science ®Google Scholar
• Busby WF, Ackermann JM, Crespi CL. (1999). Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246–249.
   PubMed Web of Science ®Google Scholar
• Chang TKH, Waxman DJ. (1998). Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2 and CYP1B1 with 7-ethoxyresorufin as a substrate, in Cytochrome P450 protocols (Phillips IR, and Shephard EA eds) pp 103–122 Totowa, NJ: Humana.
   Google Scholar
• Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Radominska-Pandya A, Tephly TR. (1999). Studies on the substrate specifity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165–1170.
   PubMed Web of Science ®Google Scholar
• Cohen S, Burns RC. (2002). Pathways of the Pulp 8th Edition, p 465, St. Louis: Mosby, Inc.
   Google Scholar
• Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO. (2001). Interindividual variability in acteaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998–1006.
   PubMed Web of Science ®Google Scholar
• Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Pasquale GD, Carson DA. (1993) New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation. J Med Chem 36:3424–3430.
   PubMed Web of Science ®Google Scholar
• Crespi CL, Chang TKH, Waxman DJ. (1998a). Determination of CYP2C9-catalyzed diclofenac 4′-hydroxylation by high-performance liquid chromatography. In Phillips IR, Shepard EA, eds. Cytochrome P450 Protocols. Totowa NJ: Humana, 129–133.
   Google Scholar
• Crespi CL, Chang TKH, Waxman DJ. (1998b). CYP2D6-dependent bufuralol 1′-hydroxylation assayed by reversed-phase ion-pair high performance liquid chromatography with fluorescence detection. In Phillips IR, Shepard EA, eds. Cytochrome P450 Protocols. Totowa, NJ: Humana, 141–146.
   Google Scholar
• Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ. (2004). Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699–706.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Abbracchio MP, Barbieri D, Ceruti S, Ferrari D, Iliou JP, Rounds S, Schubert P, Schulze-Lohoff E, Rassendren FA, Staub M, Volontè C, Wakade AR, Burnstock G. (1996). Purines and cell death. Drug Dev Res 39:442–449.
   Google Scholar
• Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B. (2003). Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica 33:1073–1083.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. (1986). Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation. J Biol Chem 261:5051–5060.
   PubMed Web of Science ®Google Scholar
• Hail N, Lotan R. (2002). Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J Natl Cancer Inst 94:1281–1292.
   PubMedGoogle Scholar
• Hanioka N, Hayashi K, Shimizudani T, Nagaoka K, Koeda A, Naito S, Narimatsu S. (2008). Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7. Pharmacology 82:293–303.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Sakai S, Honma Y. (2003). Cytokinin-induced differentiation of human myeloid leukemia HL-60 cells is associated with the formation of nucleotides, but not with incorporation into DNA or RNA. Biochim Biophys Acta 1643:11–24.
   PubMed Web of Science ®Google Scholar
• Jones DR, Moran DH, Miller GP. (2010). Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev 42:53–59.
   Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. (2002), Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30(6):697–700.
   Google Scholar
• Kerdpin O, Knights KM, Elliot DJ, Miners JO. (2000). In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Ther Drug Monitor 22(1):10–13.
   PubMedGoogle Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• King CD, Tang W, Ngui J, Tephly T, Brau M. (2001). Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49–53.
   PubMed Web of Science ®Google Scholar
• Kohno Y, Sei Y, Koshiba M, Kim HO, Jacobson KA. (1996). Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun 219:904–910.
   PubMed Web of Science ®Google Scholar
• Knights KM, Miners JO. (2010). Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev 42(1):63–73.
   PubMedGoogle Scholar
• Lin JH, Wong BK. (2002). Complexities of glucuronidation affecting in vitroin vivo extrapolation. Curr Drug Metab 3:623–646.
   PubMed Web of Science ®Google Scholar
• McClue SJ, Stuart I. (2008). Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos 36:561–570.
   PubMed Web of Science ®Google Scholar
• Michalets EL, Williams CR. (2000). Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 39:49–75.
   PubMed Web of Science ®Google Scholar
• Nekvindová J, Mašek V, Veinlichová A, Anzenbacherová E, Anzenbacher P, Zídek Z, Holý A. (2006). Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica 36:1165–1177.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. (2004). Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem 11:1693–1713.
   PubMed Web of Science ®Google Scholar
• Oleson L, Court MH. (2008). Effect of the β-glucuronidase inhibitor, saccharolactone, on glucuronidation by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175–1182.
   PubMed Web of Science ®Google Scholar
• Rathbone MP, Christjanson L, Deforge S, Deluca B, Gysbers JW, Hindley S, Jovetich M, Middlemiss P, Takhal S. (1992). Extracellular purine nucleosides stimulate cell division,and morphogenesis: pathological and physiological implications. Med Hypotheses 37:232–240.
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C. (2004). Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219–225.
   PubMed Web of Science ®Google Scholar
• Scopes J, Daly S, Atkinson R. (1996). Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Blood 87(8):3179–3185.
   PubMedGoogle Scholar
• Segel IH. (1975). Uncompetitive inhibition (simple linear uncompetitive inhibition), in Segel IH: Enzyme kinetics; behaviour and analysis of rapid equilibrium and steady-state enzyme systems pp 136–146, Wiley Classics Library Edition Published 1993, John Wiley & Sons, Inc.
   Google Scholar
• Siller M,Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. (2009). Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos 37:1198–1202.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO. (1993). High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, putative cytochrome P450 2E1 activity, in human liver microsomes. J Chromatogr 616:73–78.
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Chang TKH. (1998). Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. In Phillips IR, Shepard EA, eds. Cytochrome P450 Protocols. Totowa, NJ: Humana, 111–116
   Google Scholar
• Welte K, Dale D. (1996). Pathophysiology and treatment of severe chronic neutropenia. Annals of Hematology 72(4):158–165.
   PubMedGoogle Scholar
• Williams JA, Hyland R, Jone BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: A phamracokinetics explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Met Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar